In addition, it was approved as the first-line treatment for unresectable locally advanced or relapsed/metastatic esophageal squamous cell cancer, non-operable locally advanced or metastatic without epidermal growth factor receptor gene mutation (EGFR) and anaplastic lymphoma kinase gene fusions (ALK) non-squamous NSCLC, locally relapsed or metastatic nasopharyngeal cancer (Keam, 2019; Wang et al., 2020; Yang et al., 2020; Zhang et al., 2021). The gene discussed is ALK; the disease is esophageal squamous cell carcinoma.